Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc, a global pharmaceutical company incorporated in Ireland, filed this Current Report on Form 8-K on February 27, 2024. The filing serves to announce the release of earnings results for the fourth quarter and full year ended December 31, 2023. The detailed financial data is contained in the attached press release (Exhibit 99.1), which is not included in the text of this filing.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references the existence of both GAAP and non-GAAP financial measures but does not list the actual figures.
The company utilizes the following non-GAAP adjustments to evaluate performance:
- Adjusted gross profit and operating income
- Adjusted net income and diluted earnings per share
- Constant currency and organic net sales growth
Material Changes and Adjustments
The filing outlines specific items excluded from non-GAAP measures to facilitate period-to-period comparability. For the three months ended December 31, 2023, adjustments included:
- Impairment charges
- Amortization expense related to acquired intangible assets
- Restructuring charges and termination benefits
- Unusual litigation costs
- Acquisition and integration-related charges
- Foreign currency translation movements
For the twelve months ended December 31, 2023, additional adjustments included gains or losses on early debt extinguishment, divestitures, investment securities, and milestone payments related to royalty rights.
Guidance, Outlook, and Risks
Management states that these non-GAAP measures are used for planning, forecasting, and determining compensation. The filing emphasizes that investors should consider these measures in conjunction with, not in lieu of, GAAP financial statements. No specific forward-looking guidance, risk factors, or contingencies are detailed within the text of this 8-K filing itself.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual revenue, earnings per share, and cash flow figures.
- Verify the specific dollar amounts of impairment charges and restructuring costs excluded from non-GAAP results.
- Confirm the impact of foreign currency translation on reported sales growth.
- Check the status of the 3.900% Notes due 2024 listed in the securities section, given the filing date of February 2024.
- Compare the non-GAAP tax adjustments against the effective tax rate in the full 10-K filing.